GM-CSF has been shown to be upregulated in glioblastoma and associated with tumor growth, and demonstrated to induce expression of the IL-4 receptor in glioma myeloid cells, leading to immunosuppression in the tumor microenvironment52. This evidence concerns the gene CSF2 and central nervous system cancer.